Date Title Description PDF
07 Nov 2024 On P&L The Company releases the press release related to the first nine months 2024 financial results Download
07 Nov 2024 On P&L The Company releases the first nine months 2024 financial results presentation Download
24 Oct 2024 On corporate transactions ROVI completes the strategic review of its CDMO business Download
31 Jul 2024 On P&L The Company releases the press release related to the first half 2024 financial results Download
31 Jul 2024 On P&L The Company releases the first half 2024 financial results presentation Download

Pages

Date Title Description PDF
05 Nov 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted on 3 and 4 November Download
03 Nov 2021 On business and financial situation The Company releases the first nine months 2021 financial results presentation Download
03 Nov 2021 On business and financial situation The Company releases the press release related to the first nine months 2021 financial results Download
21 Oct 2021 Liquidity and counterparty agreements Download
21 Oct 2021 On business and financial situation The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). Download

Pages

Date Title Description PDF
05 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. Download
03 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted from 11 July to 30 September 2017   Download
07 Sep 2017 Otros sobre negocio y situación financiera The Company informs that commences the enoxaparin biosimilar marketing in Germany Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download

Pages